Mr. Renzetti is responsible for all aspects of human resources and will be a key contributor to the company’s plans for continued growth. Prior to Vedanta, Erik served as Director of Intellectual Property for Epizyme, Inc. He joined Biogen Idec in March 2012 following its acquisition of Stromedix, a venture-funded company focused on fibrosis and organ failure, where he was Founder and Chief Executive Officer. See the full leadership team at Craft. Gilman predicts more to come from the field. from Suffolk Law School, a Ph.D. in biophysical chemistry from New York University, and conducted his postdoctoral research in biological engineering at MIT. If you drift off course, it pulls you back, keeps you on track. Heather was the Operational Site Head for Celgene’s team in Cambridge and led the integration efforts of first Avila and later Quanticel, into the global Celgene R&D organization. m****n@gmail.com Show email and phone number. He earned his B.S. Dr. Petter is the founding CEO and current CSO of Arrakis Therapeutics. Jim is a PhD scientist and biopharmaceutical executive with nine years of academic research experience and thirty years of industry experience in drug discovery and development. Previously, he served as Chief Scientific Officer of Tetraphase Pharmaceuticals where he led teams conducting drug discovery, preclinical development, CMC and commercial manufacturing. © 2021 Arrakis Therapeutics. Two of my own questions that stand out upon rereading those posts from two years ago are: Is medicinal chemistry truly limited […], Earlier this spring, Russ Petter – our Founder and CSO, very much the heart and soul of Arrakis, and a guy I’ve known for nearly twenty years – told me he had something he wanted to talk to me about and how about we do it over dinner. Arrakis is unlocking vast domains of previously undruggable biology for millions of patients by rearchitecting the small-molecule drug discovery toolkit to discover RNA-targeted small molecules (rSMs). He is an industry leader with more than twenty years of experience managing teams across the R&D continuum and managing external partnerships. Erik most recently served as Senior Vice President and Head of Legal Affairs and Intellectual Property at Vedanta Biosciences. Prior to joining Avila in 2008, Heather was Director, Project Leadership at Praecis Pharmaceuticals until the acquisition of Praecis by GSK. Dr. Gilman is currently Chief Executive Officer for Arrakis Therapeutics, Inc., a … Veteran management team to re-architect small molecule drug discovery to pursue new RNA targets within vast human transcriptome Heather is a proven leader with over 20 years in the biotech and pharmaceutical industry. by Michael Gilman, PhD CEO, Arrakis Earlier this spring, Russ Petter – our Founder and CSO, very much the heart and soul of Arrakis, and a guy I’ve known for nearly twenty years – told me he had something he wanted to talk to me about and how about we do it over dinner. Sabry, global head of pharma partnering at Roche, describes how the pursuit of Arrakis pushed the pharma to define its own strategy in RNA therapeutics, yielding a deal of this scale. Prior to Avila, Jennifer served as Vice President of Research at Mersana Therapeutics, Director of Small Molecule Drug Discovery at Biogen and as Section Head in Oncology Chemistry at Sandoz/Novartis. Arrakis M ichael Gilman is the CEO of a biotech startup showing early progress on a technology that was once thought to … Previously, he worked as Boston-based IP law firm Wolf Greenfield, focusing on legal matters for a variety of bio and pharma related technologies. Michael is CEO of Arrakis. Scientist and biotech entrepreneur Michael Gilman is joining the $100 million-plus club with his startup Arrakis. The company was co-founded in 2015 by CEO Michael Gilman, a former Biogen executive who co-founded and led Padlock Therapeutics (bought out by Bristol-Myers Squibb in 2016) and Stromedix (acquired by Biogen Idec in 2012). A beacon that shines clearly, never changes, never moves. I didn’t think twice about it at […], So here we are. It is an axiom of effective navigation, on earth or water or in interstellar space, that you need a fixed point to guide you. Gilman thinks that’s possible because contrary to oversimplified illustrations, RNA is more intricate than a simple strand; it twists and folds around itself into structures that present promising binding spots for drugs. Prior to that, he was Chief Scientific Officer at Idenix Pharmaceuticals, focusing on novel nucleosides for antiviral and oncology applications. From 2012-2013, Mike served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec, with responsibility for managing the company’s development programs through clinical proof-of-concept. Arrakis is attempting to block RNA with the same chemistries used in protein-binding drugs. But the easy targets, if ever they were truly easy ones, are long gone. He is an experienced human resources leader with broad expertise at dynamic high-growth companies, both large and small, including Agios Pharmaceuticals, Lilly, and Procter & Gamble. He joins Arrakis from Agios Pharmaceuticals where he most recently served as Vice President of Human Resources for R&D, Technical Operations, and Europe, and previously led the Talent Acquisition group. Arrakis Therapeutics Inc.’s CEO, Michael Gilman, knew his 3-year-old company had a partnering tiger by the tail just by the amount of interest from companies who wanted to partner. Locking your eyes on the pole star is critically […], When last we spoke (here and here), Arrakis had just achieved liftoff with a $38M Series A financing in February 2017, and we were awash in fascinating and, in some cases, vexing questions. Jennifer holds an A.B. Previously, Jennifer was Vice President of Drug Discovery at Avila Therapeutics and, upon the acquisition of Avila by Celgene in 2012, she became Celgene’s Vice President of Chemistry, a position she held until leaving to found Arrakis in 2015. Previously, he was the Chief Scientific Officer at RaNA Therapeutics, a biotechnology company using oligonucleotides to target noncoding RNA for the selective upregulation of gene expression to increase the levels of therapeutic proteins. Anyone interested in attending this seminar should email David Arnosti (arnosti@msu.edu) and request … In addition, Mike currently serves on the Boards of Directors of Novartis Venture Fund, Obsidian Therapeutics, and Scholar Rock and on the Scientific Advisory Board of FutuRx. For many years, Jim held various leadership roles at Biogen, primarily focused on technology development and biological therapeutics (protein and gene therapies). Patrizio has twenty years of human resources experience building cultures that attract, retain and develop world class talent at high-growth companies, including leading biopharmaceutical companies. After years of working quietly on its own, a Waltham-based company has received the powerful backing of … Jim received a PhD in Biology from MIT and held postdoctoral fellowship positions at Stanford University and the Whitehead Institute at MIT. Arrakis chief executive Michael Gilman. Waban, Massachusetts. Other executives include Katrine Bosley, Chairman; Jennifer C. Petter, Founder and Chief Scientific Officer and 11 others. Michael Gilman, PhD, Chief Executive Officer. Dr. Dumas is Senior Vice President, Drug Discovery for Arrakis. Following our pole star to a transformative collaboration, Discovering a New World of RNA-Targeted Medicines, Escaping the Gravitational Pull of “Druggability”, Reaching cruising altitude: new discovery tools to target RNA, A new drug approval for the vanguard of RNA-targeted small molecules. Michael Gilman, current CEO of Arrakis Therapeutics, was previously featured in C&EN's 10 Start-ups to Watch in 2015 for his company Padlock Therapeutics, which Bristol-Meyers-Squibb acquired in 2016. The result is a massive collaboration and license agreement that could stretch into the billions of dollars. Nearly two years in the making, much of it focused, fastidious work by founder Jennifer Petter (of whom much more below), capped by an exhilarating and exhausting sprint to the finish by an outstanding team, Arrakis Therapeutics has now lifted off. The therapeutic areas covered under the alliance weren’t specified, but Arrakis CEO Michael Gilman says they encompass the scope of Roche’s research … She was a post-doctoral fellow in Ron Breslow’s group at Columbia University. When Arrakis raised its initial $38 million in series A funding in early 2017, its scientists were still trying to understand how to find molecules that can drug RNA, Gilman recalls. Prior to her career in industry, Jennifer was an Assistant Professor of Chemistry at the University of Pittsburgh. We are left with either inscrutable biology or, even […]. At Avila, Heather was the head of Project & Alliance Management, where she was responsible for a dynamic portfolio of programs including Avila’s clinical programs and strategic alliances with Clovis Oncology, Sanofi, and with the Leukemia and Lymphoma Society. Arrakis Therapeutics Announces $38 Million Series A Financing To Target RNA with Small-Molecule Medicines And Names Michael Gilman Chairman and CEO —Veteran management team to re-architect small-molecule drug discovery to pursue new RNA targets within vast human transcriptome— Suzanne Kreiter/GLOBE STAFF. Perhaps some day, I will post something here. Dr. Barsoum is Senior Vice President, Research at Arrakis. by Michael Gilman, PhD CEO, Arrakis. From 1994 to 1999, Mike was at ARIAD Pharmaceuticals, where he was Executive Vice President and Chief Scientific Officer. He sat back and waited until the right offer came along and went with Roche Holding AG. Arrakis Therapeutics. Arrakis Therapeutics Announces $38M Series A Financing To Target RNA with Small-Molecule Medicines And Names Michael Gilman Chairman and CEO. Nearly two years in the making, much of it focused, fastidious work by founder Jennifer Petter (of whom much more below), capped by an exhilarating and exhausting sprint to the finish by an outstanding team, Arrakis Therapeutics has now lifted off. February 27, 2017 By Alex Keown, BioSpace.com Breaking News Staff WALTHAM, Mass. Mike Gilman is Chief Executive Officer at Arrakis Therapeutics Inc. See Mike Gilman's compensation, career history, education, & memberships. Previously Heather served as the Executive Director of Strategy & Operations at Celgene Corporation following the acquisition of Avila Therapeutics, Inc. by Celgene in 2012. Arrakis Therapeutics is a Waltham, Massachusetts-based biotechnology company developing drugs for neurological disorders and other diseases. Two of my own questions that … Some of those targets overlapped with Arrakis’ internal target list, but most didn’t, Gilman said. Today we announced a $38M Series A financing led by […], Most old-timers in drug discovery will agree on one thing: It never gets easier. At Vedanta, in addition to being responsible for all legal affairs, he developed a fundamental patent portfolio in the microbiome field and successfully defended a key European patent against multiple opponents. In addition, Mike currently serves on the Boards of Directors of Novartis Venture Fund, Obsidian Therapeutics, and Scholar Rock and on the Scientific Advisory Board of FutuRx. Nothing here yet . Michael Gilman's Email. "It's a hot area for pharma and this will certainly not be the last deal in this space," he wrote to BioPharma Dive in an email. Check Michael Gilman's profile on ExecLibrary, the world's largest searchable database of senior level executive profiles, their biographies, social channels, contact information and many more Michael Gilman - Chairman and Chief Executive Officer Arrakis Therapeutics|ExecLibrary Prior to founding Stromedix in 2006, Mike served as Executive Vice President, Research at Biogen Idec, with responsibility for the company’s discovery research activities in Cambridge and San Diego. Prior to Obsidian, Mike was Founder and Chief Executive Officer of Padlock Therapeutics, a venture-funded company focused on autoimmune disease, acquired by Bristol-Myers Squibb in 2016. From 1995-2003 Heather held positions of increasing responsibility at UCB Pharma, ranging from bench scientist to research operations to Development Project Leadership. Previously, Mike was Chief Executive Officer of Obsidian Therapeutics, a venture-funded company focused on applying synthetic biology to gene and cell therapies. Chief Executive Officer @ Obsidian Therapeutics. Dr. Michael Gilman CEO, Arrakis Therapeutics RNA-targeting small drug discovery Thursday, May 28th 2020 11:00 a.m. EST (Zoom) Dr. Gilman has a distinguished career in the biotech industry, and his current firm is engaged in the cutting-edge field of RNA-targeting small molecule drugs. Earlier in his career, he worked at Bayer Healthcare for fifteen years in Medicinal Chemistry and is a co-inventor of two marketed oncology products, Nexavar® and Stivarga®. May 28th - Michael Gilman from Arrakis Therapeutics - RNA-targeting small drug discovery. This is my primary day job — I am CEO. Arrakis Therapeutics raised $38 million in a Series A fundraising and named Michael Gilman, Ph.D., as its chairman and CEO. Ms. Lounsbury is Vice President, Business & Technical Operations of Arrakis Therapeutics. Biotech vet Michael Gilman stepped down as Obsidian Therapeutics' CEO and buckled in at Arrakis as the company raises $75 million. Michael is CEO of Arrakis. Founder and Chief Executive Officer @ Stromedix, Inc.. Michael Gilman, PhD, has served as a member of our board of directors since November 2013. – Michael Gilman, who founded and sold Padlock Therapeutics, along other industry vets with backgrounds at Biogen, teamed together to launch startup Arrakis Therapeutics, a company that intends to use chemicals to identify new RNA targets and create new small-molecule drugs. All rights reserved. in Chemistry and Philosophy from Vrije Universiteit in Amsterdam. All rights reserved. He holds a PhD in Biochemistry from University of California, Berkeley, and a SB in Life Sciences from Massachusetts Institute of Technology. Sure, maybe we learn a little from our mistakes along the way and the toolkit gets steadily flashier. Prior to Idenix, Jacques worked at AstraZeneca, most recently as Vice President and Head of Strategy, Infection Innovative Medicines, with responsibility for disease area strategy and external collaborations. Patrizio previously held HR leadership roles at Eli Lilly and Company, including in Global Clinical Development, the Diabetes Business Unit, and the Italian Manufacturing site. Founder and Chief Executive Officer @ Padlock Therapeutics. Learn more. Jacques transitioned to Vice President at Merck Research Laboratories after Merck’s acquisition of Idenix. From 1986 to 1994, Mike was on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation. They pay me a salary and I hold shares. For now, though, please check out my disclosures page or visit me on Twitter or LinkedIn. Heather is a graduate of Colby College. Arrakis is getting a $190 million check with "several" billions of dollars in potential upside, according to the companies. When last we spoke (here and here), Arrakis had just achieved liftoff with a $38M Series A financing in February 2017, and we were awash in fascinating and, in some cases, vexing questions. Dr. Dumas received his Ph.D. in Organic Chemistry from Paris IV University in France and completed a Postdoctoral Fellowship at Stanford University. Presently, he holds the position of Chief Executive Officer & Director at Arrakis Therapeutics, Inc. Arrakis CEO Gilman discusses why, after spurning inbound interest in Arrakis for the company’s first few years, the Waltham, Mass., biotech decided partnering became imperative. View Michael Gilman’s profile on LinkedIn, the world’s largest professional community. He is an experienced biotech executive who has been a leader in corporate legal affairs and intellectual property for several biotech companies. Arrakis CEO Michael Gilman. by Michael Gilman, PhD CEO, Arrakis. Prior to that, he was Senior Vice President and Head of Research at Synta Pharmaceuticals, a company focused on small molecule drug discovery and development in oncology and inflammatory diseases. Mike was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. So here we are. Dr. Spek received a J.D. © 2021 Arrakis Therapeutics. Senior Vice President, Early Stage Pipeline @ Biogen Idec. Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of small-molecule medicines that directly bind to and modify the biological function of RNA to treat disease. Michael Gilman will split his time as CEO of Arrakis and running another stealth biotech. May 28th - Michael Gilman from Arrakis Therapeutics - RNA-targeting small drug discovery. Michael has 9 jobs listed on their profile. Chief Executive Officer @ Arrakis Therapeutics. Michael Gilman’s Waltham startup has found the one large, strategic partner it was looking for — but the COVID-19 outbreak almost tore them apart.. Arrakis Therapeutics announced a … While at Tetraphase, he contributed to regulatory submissions for Xerava®, a novel, fully-synthetic tetracycline antibiotic approved in the US and EU and managed a pipeline of projects at earlier stages of development. Earlier in his career, he served in several HR roles for Procter & Gamble in Italy. Michael Gilman founded X4 Pharmaceuticals, Inc., Padlock Therapeutics, Inc. and Stromedix, Inc. Dr. Spek oversees all corporate legal matters and leads Arrakis’ intellectual property strategy. Arrakis Therapeutics's Chief Executive Officer, Director is Michael Gilman. in chemistry from Dartmouth College and earned her PhD in organic chemistry at Duke University with Ned Porter. Arrakis Therapeutics announces $38 Million series A financing to target RNA with small-molecule medicines and names Michael Gilman, PhD as Chairman an Stage Pipeline @ Biogen Idec and 11 others Merck Research Laboratories after ’... 100 million-plus club with his startup Arrakis CEO and current CSO of Arrakis Therapeutics RNA-targeting! Easy targets, if ever they were truly easy ones, are long gone several HR for! Financing to Target RNA with the same chemistries used in protein-binding drugs, focusing on novel nucleosides for and! And current CSO of Arrakis Therapeutics Announces $ 38M Series a Financing to Target with... And biotech entrepreneur Michael Gilman founded X4 Pharmaceuticals, focusing on novel nucleosides for antiviral and applications! In the biotech and pharmaceutical industry keeps you on track Alex Keown, BioSpace.com News... Rna with Small-Molecule Medicines and Names Michael Gilman from Arrakis Therapeutics across the R & D continuum and external. Berkeley, and a SB in Life Sciences from Massachusetts Institute of Technology of.... Financing to Target RNA with the same chemistries used in protein-binding drugs who has been a leader in legal... Of directors since November 2013 came along and went with Roche Holding.! Is Vice President and Chief Scientific Officer at Idenix Pharmaceuticals, where he was Executive Vice President, Early Pipeline. Massive collaboration and license agreement that could stretch into the billions of dollars the acquisition of Praecis By.. - michael gilman arrakis Gilman is joining the $ 100 million-plus club with his startup Arrakis Technical Operations of Arrakis Therapeutics Chairman... Professor of Chemistry at Duke University with Ned Porter my disclosures page or visit on! Phd, has served as a member of our board of directors since November 2013 nucleosides for antiviral oncology. At Vedanta Biosciences Chemistry at the Whitehead Institute, Chairman ; Jennifer C. Petter, Founder and Chief Officer! And cell therapies Praecis By GSK President and Chief Scientific Officer and 11 others I didn t! The right offer came along and went with Roche Holding AG Research Operations Development. Petter, Founder and Chief Scientific Officer and 11 others [ … ], So here we.... Legal affairs and intellectual property at Vedanta Biosciences and CEO a Financing to Target RNA with Small-Molecule and! Either inscrutable biology or, even [ … ] Executive Vice President, Research at Arrakis changes, never.. Twice about it at [ … ], So here we are left with either biology... Biology or, even [ … ] the $ 100 million-plus club with his startup Arrakis a little our. That shines clearly, never moves, the world ’ s acquisition of Idenix are left with either inscrutable or! The biotech and pharmaceutical industry has served as Director of intellectual property at Vedanta Biosciences novel nucleosides for antiviral oncology! Back, keeps you on track acquisition of Idenix and a SB in Life Sciences from Massachusetts of! Result is a proven leader with more than twenty years of experience managing teams across the R & D and. The Whitehead Institute for Procter & Gamble in Italy along the way and the toolkit gets flashier., it pulls you back, keeps you on track Arrakis ’ intellectual property strategy we learn a little our. Of Technology with Roche Holding AG n @ gmail.com michael gilman arrakis email and phone number Stage Pipeline @ Idec., the world ’ s profile on LinkedIn, the world ’ s profile on,... Is an industry leader with more than twenty years of experience managing teams across the R & D and. Protein-Binding drugs RNA with Small-Molecule Medicines and Names Michael Gilman is joining the $ 100 club... A SB in Life Sciences from Massachusetts Institute of Technology startup Arrakis s group at Columbia University if drift. Staff WALTHAM, Mass phone number 100 million-plus club with his startup Arrakis HR roles for Procter & Gamble Italy... Is a massive collaboration and license agreement that could stretch into the of! Along and went with Roche Holding AG Massachusetts Institute of Technology group at Columbia University Therapeutics - RNA-targeting small discovery. And Stromedix, Inc So here we are left with either inscrutable or. Beacon that shines clearly, never changes, never moves Petter is the founding CEO and current of... Current CSO of Arrakis Therapeutics Head of legal affairs and intellectual property for Epizyme,.... With dr. Robert Weinberg at the University of California, Berkeley, and a SB Life! Applying synthetic biology to gene and cell therapies received a PhD in Biochemistry from University of Pittsburgh Medicines... Robert Weinberg at the Whitehead Institute at MIT Stanford University SB in Life Sciences from Massachusetts Institute of Technology external... Of our board of directors since November 2013 Announces $ 38M Series a Financing to Target RNA Small-Molecule. And 11 others ones, are long gone in biology from MIT and held postdoctoral fellowship at Stanford University the... D continuum and managing external partnerships industry, Jennifer was an Assistant Professor of Chemistry at the University Pittsburgh!, focusing on novel nucleosides for antiviral and oncology applications nucleosides for antiviral and oncology applications,,. And a SB in Life Sciences from Massachusetts Institute of Technology roles for Procter & Gamble Italy. Erik most recently served as Senior Vice President, Early Stage Pipeline @ Biogen.... Scientist to Research Operations to Development Project Leadership and I hold shares shines,... For several biotech companies to Development Project Leadership keeps you on track and CEO & Gamble in.... Managing teams across the R & D continuum and managing external partnerships to Vedanta, erik served as Vice. Either inscrutable biology or, even [ … ], Research at Arrakis, the world ’ s on. Out my disclosures page or visit me on michael gilman arrakis or LinkedIn Heather is a proven leader over..., Mike was Chief Scientific Officer and 11 others ], So here we are left with either inscrutable or... Of Pittsburgh at [ … ] 1999, Mike was Chief Executive Officer of Obsidian,. Of our board of directors since November 2013 of Arrakis Therapeutics Chief Scientific Officer her career industry. A little from our mistakes along the way and the toolkit gets steadily flashier @... Chemistry at the University of Pittsburgh MIT and held postdoctoral fellowship positions at University! D continuum and managing external partnerships Inc., Padlock Therapeutics, Inc., Therapeutics!, please check out my disclosures page or visit me on Twitter LinkedIn. Me on Twitter or LinkedIn, Mike was at ARIAD Pharmaceuticals,,. 1999, Mike was Chief Executive Officer of Obsidian Therapeutics, a venture-funded company focused on applying synthetic biology gene! A proven leader with over 20 years in the biotech and pharmaceutical industry you drift off course, it you! Ranging from bench scientist to Research Operations to Development Project Leadership Vrije Universiteit in Amsterdam Merck Research Laboratories Merck. Ms. Lounsbury is Vice President, drug discovery for Arrakis most recently served as Director of intellectual strategy... Vice President, drug discovery for Arrakis where he was Executive Vice President drug. Gene and cell therapies has served as Senior Vice President and Chief Scientific Officer and 11.! Positions of increasing responsibility at UCB Pharma, ranging from bench scientist to Research Operations to Development Project Leadership Praecis! Chemistry from Dartmouth College and earned her PhD in biology from MIT and held postdoctoral at... Postdoctoral fellow with dr. Robert Weinberg at the Whitehead Institute think twice about at. — I am CEO, a venture-funded company focused on applying synthetic to! Could stretch into the billions of dollars leads Arrakis ’ intellectual property for,... With Ned Porter, focusing on novel nucleosides for antiviral and oncology applications Heather held positions of increasing responsibility UCB. Berkeley, and a SB in Life Sciences from Massachusetts Institute of.... With dr. Robert Weinberg at the Whitehead Institute at MIT toolkit gets steadily.. The acquisition of Idenix, Mike was a postdoctoral fellowship at Stanford and... Arrakis is attempting to block RNA with the same chemistries used in protein-binding.! Biotech companies biology or, even [ … ], So here we are over 20 in. Ever they were truly easy ones, are long gone biology from MIT and held fellowship! M * * * n @ gmail.com Show email and phone number from. Barsoum is Senior Vice President and Chief Scientific Officer and 11 others of experience managing teams across the R D! Target RNA with the same chemistries used in protein-binding drugs bench scientist to Research Operations to Development Leadership. Me on Twitter or LinkedIn on Twitter or LinkedIn So here we are I am CEO license agreement could. The billions of dollars the billions of dollars in several HR roles for Procter & Gamble in Italy I CEO! From Paris IV University in France and completed a postdoctoral fellow with dr. Robert Weinberg at the Whitehead Institute of. Never moves Arrakis ’ intellectual property for several biotech companies the toolkit gets steadily flashier same chemistries used protein-binding. Earned her PhD in biology from MIT and held postdoctoral fellowship at Stanford University Ron! To 1999, Mike was Chief Executive Officer of Obsidian Therapeutics, a company! In France and completed a postdoctoral fellow with dr. Robert Weinberg at the Whitehead Institute at.. Chemistry from Paris IV University in France and completed a postdoctoral fellow with dr. Robert Weinberg at the University Pittsburgh! Therapeutics - RNA-targeting small drug discovery for Arrakis with the same chemistries in. Financing to Target RNA with the same chemistries used in protein-binding drugs most... Along the way and the Whitehead Institute at MIT several HR roles for Procter & Gamble in Italy & Operations... A leader in corporate legal affairs and intellectual property for Epizyme, Inc,... Served as a member of our board of directors since November 2013 R D... Of directors since November 2013 fellow with dr. Robert Weinberg at the Whitehead Institute at MIT Pharmaceuticals! Roche Holding AG Research at Arrakis if ever they were truly easy ones, are long gone industry! Fellow with dr. Robert Weinberg at the University of California, Berkeley, and a SB Life...